Search Results
You are looking at 1 - 10 of 19 items for
- Author: Martin Schlumberger x
- Refine by access: All content x
Search for other papers by Livia Lamartina in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Marie Terroir in
Google Scholar
PubMed
Search for other papers by Dana Hartl in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Low-risk papillary cancers, which represent the vast majority of thyroid cancers diagnosed today, do not require aggressive treatment or follow-up. Initial treatment consists of a total thyroidectomy without prophylactic lymph node dissection. A hemithyroidectomy is an alternative in some patients with an intrathyroidal tumor and with a normal contralateral lobe at pre-operative neck ultrasonography. The use of post-operative radioiodine should be restricted to selected patients. Follow-up at 6–18 months is based on serum thyroglobulin (Tg), Tg-antibody determination and neck ultrasonography. In the absence of any abnormality (excellent response to treatment), the risk of recurrence is extremely low and follow-up may consist of serum TSH monitoring that is maintained in the normal range, and a Tg and Tg-antibody titer determination every year. There is no need for referral to a specialized center. In patients with detectable serum Tg or detectable Tg antibodies, the trend over time of these markers on levothyroxine treatment will dictate subsequent follow-up: a decreasing trend is reassuring, but an increasing trend should lead to imaging, starting with neck ultrasonography.
Search for other papers by Livia Lamartina in
Google Scholar
PubMed
Search for other papers by Nadège Anizan in
Google Scholar
PubMed
Search for other papers by Corinne Dupuy in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Based on experimental data, the inhibition of the MAPkinase pathway in patients with radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary data obtained in a small series of patients were encouraging and this strategy might become an alternative treatment in those patients with a druggable mutation that induces a stimulation of the MAP kinase pathway. This is an active field of research to answer many still unresolved questions.
Search for other papers by Maria Angela De Stefano in
Google Scholar
PubMed
Search for other papers by Tommaso Porcelli in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
CEINGE Biotecnologie Avanzate Scarl, Naples, Italy
Search for other papers by Domenico Salvatore in
Google Scholar
PubMed
The three deiodinase selenoenzymes are key regulators of intracellular thyroid hormone (TH) levels. The two TH-activating deiodinases (type 1 deiodinase and type 2 deiodinase (D2)) are normally expressed in follicular thyroid cells and contribute to overall TH production. During thyroid tumorigenesis, the deiodinase expression profile changes to customize intracellular TH levels to different requirements of cancer cells. Differentiated thyroid cancers overexpress the TH-inactivating type 3 deiodinase (D3), likely to reduce the TH signaling within the tumor. Strikingly, recent evidence suggests that during the late stage of thyroid tumorigenesis, D2 expression raises and this, together with a reduction in D3 expression levels, increases TH intracellular signaling in dedifferentiated thyroid cancers. These findings call into question the different functions of TH in the various stages of thyroid cancers.
Search for other papers by Amandine Berdelou in
Google Scholar
PubMed
Search for other papers by Livia Lamartina in
Google Scholar
PubMed
Search for other papers by Michele Klain in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by on behalf of the TUTHTYREF Network in
Google Scholar
PubMed
Distant metastases from thyroid cancer of follicular origin are uncommon. Treatment includes levothyroxine administration, focal treatment modalities with surgery, external radiation therapy and thermal ablation, and radioiodine in patients with uptake of 131I in their metastases. Two-thirds of distant metastases become refractory to radioiodine at some point, and when there is a significant tumor burden and documented progression on imaging, a treatment with a kinase inhibitor may provide benefits.
Search for other papers by Tommaso Porcelli in
Google Scholar
PubMed
Search for other papers by Raffaele Ambrosio in
Google Scholar
PubMed
Search for other papers by Maria Angela De Stefano in
Google Scholar
PubMed
Search for other papers by Cristina Luongo in
Google Scholar
PubMed
Search for other papers by Daniela Terracciano in
Google Scholar
PubMed
Search for other papers by Caterina Miro in
Google Scholar
PubMed
Search for other papers by Monica Dentice in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
CEINGE Biotecnologie Avanzate Scarl, Naples, Italy
Search for other papers by Domenico Salvatore in
Google Scholar
PubMed
Treatment with tyrosine kinase inhibitors (TKIs) has been associated with alterations in circulating thyroid hormone levels, possibly related to perturbations in peripheral thyroid hormone metabolism. In this study, we evaluated the effect of the multi-kinase inhibitor vandetanib on the expression of the three deiodinase selenoenzymes, responsible for the thyroid hormone activation (type 1 and type 2 deiodinases) or for its inactivation (type 3 deiodinase). Here, we show that the multi-kinase inhibitor vandetanib determines a strong cell-specific downregulation of type 2 deiodinase (D2) expression and a significant reduction in D2 enzymatic activity. This occurs in the diffused population of fibro/adipogenic progenitors, which reside in different tissues – including the muscles – and normally express D2. Given the widespread diffusion of mesenchymal cells within the body, our results may explain at least partially the alterations in thyroid hormone levels that occur in vandetanib-treated patients. Our findings represent a step forward into the understanding of the mechanisms by which TKIs induce hypothyroidism and identify a resident cell population in which such an effect takes place.
Search for other papers by Maria Angela De Stefano in
Google Scholar
PubMed
Search for other papers by Tommaso Porcelli in
Google Scholar
PubMed
Search for other papers by Raffaele Ambrosio in
Google Scholar
PubMed
Search for other papers by Cristina Luongo in
Google Scholar
PubMed
Search for other papers by Maddalena Raia in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
CEINGE Biotecnologie Avanzate Scarl, Naples, Italy
Search for other papers by Domenico Salvatore in
Google Scholar
PubMed
Anaplastic thyroid cancer (ATC) is a rare thyroid tumor that frequently originates from the dedifferentiation of a well-differentiated papillary or follicular thyroid cancer. Type 2 deiodinase (D2), responsible for the activation of the thyroid hormone thyroxine into tri-iodothyronine (T3), is expressed in normal thyroid cells and its expression is strongly downregulated in papillary thyroid cancer. In skin cancer, D2 has been associated with cancer progression, dedifferentiation, and epithelial–mesenchymal transition. Here, we show that D2 is highly expressed in anaplastic compared to papillary thyroid cancer cell lines and that D2-derived T3 is required for ATC cell proliferation. D2 inhibition is associated with G1 growth arrest and induction of cell senescence, together with reduced cell migration and invasive potential. Finally, we found that mutated p5372R(R248W), frequently found in ATC, is able to induce D2 expression in transfected papillary thyroid cancer cells. Our results show that the action of D2 is crucial for ATC proliferation and invasiveness, providing a potential new therapeutic target for the treatment of ATC.
Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Search for other papers by Johannes Smit in
Google Scholar
PubMed
Search for other papers by Chia-Chi Lin in
Google Scholar
PubMed
Search for other papers by Fabian Pitoia in
Google Scholar
PubMed
Search for other papers by Marc Fellous in
Google Scholar
PubMed
Search for other papers by Yoriko DeSanctis in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Masayuki Tori in
Google Scholar
PubMed
Search for other papers by Iwao Sugitani in
Google Scholar
PubMed
There are limited treatment options for patients with radioactive iodine refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease, uncertainty exists on the optimal timing to treat with a multikinase inhibitor, especially for asymptomatic patients. RIFTOS MKI is an international, prospective, open-label, multicenter, noninterventional study with the primary objective to compare the time to symptomatic progression from study entry in asymptomatic patients with radioactive iodine refractory, progressive differentiated thyroid cancer for whom there is a decision to initiate multikinase inhibitors at study entry (cohort 1) with those for whom there is a decision to not initiate multikinase inhibitors at study entry (cohort 2). Secondary endpoints are overall survival and progression-free survival, which will be compared between cohorts 1 and 2. Additional secondary endpoints are postprogression survival from time of symptomatic progression, duration of and response to each systemic treatment regimen and dosing of sorafenib throughout the treatment period. Asymptomatic, multikinase inhibitor-naive patients aged ≥18 years with histologically/cytologically documented differentiated thyroid cancer that is radioactive iodine refractory are eligible. Patients may receive any therapy for differentiated thyroid cancer, including sorafenib or other multikinase inhibitors if indicated and decided on by the treating physician. In total, 700 patients are estimated to be enrolled from >20 countries. Final analysis will be performed once the last enrolled patient has been followed up with for 24 months (ClinicalTrials.gov identifier: Nbib2303444).
Search for other papers by Nabahet Ameur in
Google Scholar
PubMed
CNRS FRE 2939, Translational Research Laboratory, Department of Nuclear Medicine and Endocrine Oncology, Functional Genomic Unit
Search for other papers by Ludovic Lacroix in
Google Scholar
PubMed
Search for other papers by Sophie Roucan in
Google Scholar
PubMed
Search for other papers by Véronique Roux in
Google Scholar
PubMed
Search for other papers by Sophie Broutin in
Google Scholar
PubMed
Search for other papers by Monique Talbot in
Google Scholar
PubMed
Search for other papers by Corinne Dupuy in
Google Scholar
PubMed
Search for other papers by Bernard Caillou in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
CNRS FRE 2939, Translational Research Laboratory, Department of Nuclear Medicine and Endocrine Oncology, Functional Genomic Unit
Search for other papers by Jean-Michel Bidart in
Google Scholar
PubMed
RET oncogene mutations are found in familial medullary thyroid carcinomas (MTC) and in one-third of sporadic cases. Oncogenic mechanisms involved in non-RET mutated sporadic MTC remain unclear. To study alterations associated with the development of both inherited and sporadic MTC, pangenomic DNA microarrays were used to analyze the transcriptome of 13 MTCs (four familial and nine sporadic). By using an ANOVA test, a list of 173 gene sequences with at least a twofold change expression was obtained. A subset of differentially expressed genes was controlled by real-time quantitative PCR and immunohistochemistry on a larger collection of MTCs. The expression pattern of those genes allowed us to distinguish two groups of sporadic tumors. The first group displays an expression profile similar to that expressed by inherited RET634 tumors. The second presents an expression profile close to that displayed by inherited RET918 tumors and includes tumors from patients with distant metastases. It is characterized by the overexpression of genes involved in proliferation and invasion (PTN, ESM1, and CEACAM6) or matrix remodeling (COL1A1, COL1A2, and FAP). Interestingly, RET918 tumors showed overexpression of the PTN gene, encoding pleiotrophin, a protein associated with metastasis. Using a MTC cell line, silencing of RET induced the inhibition of PTN gene expression. Overall, our results suggest that familial MTC and sporadic MTC could activate similar oncogenic pathways.
Search for other papers by Cecile N Chougnet in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Caroline Caramella in
Google Scholar
PubMed
Search for other papers by Jean Lumbroso in
Google Scholar
PubMed
Search for other papers by Isabelle Borget in
Google Scholar
PubMed
Search for other papers by Désirée Déandreis in
Google Scholar
PubMed
Search for other papers by Pierre Duvillard in
Google Scholar
PubMed
Search for other papers by Dominique Elias in
Google Scholar
PubMed
Search for other papers by Thierry de Baere in
Google Scholar
PubMed
Search for other papers by Fritz-Line Vélayoudom-Céphise in
Google Scholar
PubMed
Search for other papers by Joël Guigay in
Google Scholar
PubMed
Search for other papers by Michel Ducreux in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
Recent studies suggest that the somatostatin receptor scintigraphy (SRS) grade of uptake is a predictor of response to peptide receptor radionuclide therapy (PRRT). To identify and characterize patients with well-differentiated (WD) neuroendocrine neoplasm (NEN) displaying a high-grade uptake at SRS. Patients with WD-NEN, whose SRS films were available for review, were retrospectively included. SRS was reviewed by three independent readers and classified into four subgroups based on a modified Krenning's scale (mKS): no uptake (group-0), homogeneous grade 1–2 uptake (group-1), homogeneous grade 3–4 (group-2), and heterogeneous grade 1–4 (group-3). A simplified scale (sS) of SRS was also used to look for characteristics of patients with high-grade uptake. One hundred and six WD-NEN patients were enrolled. Group-0, group-1, group-2, and group-3 were found in 17, 8, 33, and 42% of cases respectively. High-grade uptake at sS (75% of cases) was correlated with older age, functioning NEN, high chromogranin-A level, and grade 1 (G1) NEN based on mitotic count. Based on the mKS or sS scales, no difference on survival was found. Thirty-three to seventy-five percent of metastatic NEN patients can be considered candidates for PRRT based on homogeneous or heterogeneous high-grade uptake. Functioning G1 NEN patients could be the best candidates for PRRT. Randomized trials are expected to confirm this result.
Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences ‘Mario Serio’, University of Florence, Florence, Italy
Search for other papers by Clotilde Sparano in
Google Scholar
PubMed
Search for other papers by Yann Godbert in
Google Scholar
PubMed
Search for other papers by Marie Attard in
Google Scholar
PubMed
Search for other papers by Christine Do Cao in
Google Scholar
PubMed
Search for other papers by Slimane Zerdoud in
Google Scholar
PubMed
Search for other papers by Nathalie Roudaut in
Google Scholar
PubMed
Search for other papers by Charlotte Joly in
Google Scholar
PubMed
Search for other papers by Amandine Berdelou in
Google Scholar
PubMed
Search for other papers by Julien Hadoux in
Google Scholar
PubMed
Search for other papers by Livia Lamartina in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Anaplastic thyroid cancer (ATC) is a rare lethal disease. Lenvatinib is an off-label therapeutic option for ATC in most countries, except in Japan. The aim of this multicenter retrospective survey was to analyze the efficacy and the toxicity profile of off-label lenvatinib treatment in all adults advanced ATC patients, in France. Of the 23 patients analysed (14 males; mean age 64 years), 15 were pure ATC and 8 were mixed tumors (i.e. with a differentiated or poorly differentiated component). Prior treatments included neck external beam irradiation in 74%, at least one line of chemotherapy in 22 cases, two lines of chemotherapy in 11 patients, other TKI in 4 cases. A central RECIST assessment was performed. Since lenvatinib initiation, median PFS was 2.7 months (95% CI; 1.9–3.5) and median OS was 3.1 months (95% CI; 0.6–5.5). OS was significantly longer in case of mixed tumors compared with pure ATC (6.3 vs 2.7 months, P = 0.026). Best tumor response was partial response in two cases and stable disease in seven. Clinical improvement was achieved in seven patients. Lethal adverse events occurred in three patients, consisting in haemoptysis in two cases and pneumothorax in one case. Among long-surviving ATC patients (>6 months), four underwent biopsy of distant metastasis, revealing poorly differentiated histology; three of them had initial mixed ATC histology. Efficacy of lenvatinib appears limited, although pure vs mixed ATC disclose differences in disease aggressiveness and treatment response. Long-surviving ATC patients might benefit from biopsy of persistent disease, searching for histological transition or molecular target.
